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Abstract
Background: Being diagnosed with mitochondrial disease due to the m.3243A > G mutation is frequently
preceded by a long diagnostic process. The disease itself is characterized by heterogeneous course and expression,
so leaving patients with considerable uncertainty regarding their prognosis and treatment possibilities. This could
easily result in fear of disease progression. This study investigated the presence of this fear and its correlates with
genetic characteristics and clinical disease severity in m.3243A > G carriers.
Methods: In total 125 eligible m.3243A > G mutation carriers were invited to participate in this cross-sectional
study. After informed consent, participants completed questionnaires including items on socio-demographics, fear
of progression, depression, anxiety, and quality of life. Clinical disease severity was assessed by the NMDAS
questionnaire. Heteroplasmy levels were assessed in leucocytes, urine epithelial cells and buccal mucosa.
Results: Seventy-six carriers participated in this study. Results showed that 18% reported high fear of progression.
Fear of progression was significantly related to all domains of quality of life. Furthermore, fear of progression was
moderately correlated with feelings of depression (r = .37), and anxiety (r = .44). Patients with moderate or severe
clinical symptoms on the NMDAS experienced more fear of progression than patients with mild clinical symptoms.
Fear of progression was weakly correlated with heteroplasmy in leucocytes (r = .27) and buccal mucosa (r = .31).
Conclusions: A substantial part of m.3243A > G mutation carriers experience high levels of fear of progression
which coincide with significantly lower quality of life. Only a small relation with disease characteristics was found.
The impact of receiving a diagnosis without therapeutic possibilities on fear is important to consider.
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Background
Fear of disease progression (FoP) is amongst the most
important stressors for patients with a life-threatening
disease [1]. Mitochondrial diseases are rare multi-system
diseases that result from problems due to disturbed
mitochondrial oxidative phosphorylation, the final path-
way in the production of ATP, caused by mutations in
either the nuclear or mitochondrial DNA [2–4]. Failure
of the mitochondria to perform normally results a.o. in
decreased energy production, cell injury or cell death,
and eventual organ dysfunction or failure [5]. Although
new pharmacological interventions are being explored,
currently no cure or substantially alleviating therapy is
available for these disorders and care is focused on alle-
viating the broad range of symptoms of the disease [6].
Many different genetic defects of mtDNA exist which,
in general, may cause a specific clinical syndrome. How-
ever, the relationship between genotype and phenotype
is not absolute and syndromes might overlap [7]. The
life of the individual with mitochondrial disease can be
greatly compromised, according to the degree and na-
ture of mitochondrial malfunction. The serious nature
and erratic, complex presentation of mitochondrial dis-
ease often make it difficult to establish a diagnosis and
may contribute to increased stress and worry among pa-
tients and their relatives.
Fear of disease progression has been defined as a re-
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serious, potential life-threatening or disabling disease or
its treatment [1]. Since a mitochondrial disease has ser-
ious consequences in most patients, they perceive dis-
ease progression as a realistic threat. In this respect, FoP
does not belong to the group of anxiety disorders for
which an irrational fear is usually one of the key charac-
teristics. Basically, FoP is an appropriate response to the
real threats of diagnosis, treatments and course of ill-
ness. However, the level of FoP can range between func-
tional and dysfunctional ends. Elevated levels of fear of
progression that become dysfunctional, affecting quality
of life, are in need for treatment [8]. Previous studies re-
vealed that FoP was evident in other patients with can-
cer, rheumatoid arthritis, diabetes mellitus, Parkinson’s
disease, Crohn’s disease, and multiple sclerosis [1, 9].
However, information on the impact of a rare disease
without therapeutic possibilities, a very heterogeneous
course and a hereditary character on FoP is scarce.
The aim of the present study is to investigate the
prevalence of fear of progression in patients with a mito-
chondrial disease. In addition, demographical, medical
and psychological correlates of fear of progression are
assessed. We focused on patients with a clinically and
genetically heterogeneous phenotype known as the
MELAS spectrum disorders, most commonly caused by
the m.3243 A > G mutation in mitochondrial DNA. This
spectrum is characterized by decreased exercise toler-
ance, elevated lactic acid levels, cardiac abnormalities,
diabetes, and neurological symptoms like migraine, psy-
chiatric problems, seizures, ataxia, myopathy, impaired
vision or hearing, or disturbances in consciousness [10].
Methods
Participants
Patients with a mitochondrial disease due to the m.3243
A > G mutation of the Radboud Center for mitochon-
drial medicine, were invited to participate in this study.
Participants had to be able to read and write in Dutch.
Procedure
This cross-sectional study was part of a longitudinal ob-
servational cohort study on patient reported outcomes ap-
proved (NL32683.091.10) by the local ethical committee
of the Radboud university medical center, Nijmegen, the
Netherlands. Patients were invited to participate in the
study by their treating physician. After given informed
consent, patients received an email with a link to a private,
secure website that presented a set of questionnaires on
demographic variables and psychological factors that
could be administered at home at time of first access or
later. Patients were asked to complete the total set of
questionnaires within 1 week. The Newcastle Mitochon-
drial Disease Assessment Scale (NMDAS) [11] was
assessed during clinical investigation. Questionnaires
regarding FoP were added in the last phase of the longitu-
dinal study (two to five years after baseline) and analyzed
for this study.
Instruments
Genotype was assessed in terms of heteroplasmy levels
of the m.3243A > G mutation in leucocytes, urine epithe-
lial cells and buccal mucosa.
Disease Manifestation was assessed by the Newcastle
Mitochondrial Disease Scale [11]. The NMDAS is a vali-
dated method to monitor the clinical expression of mito-
chondrial disease and to follow-up the course of the
disease in time. It consists of the following three sec-
tions: (1) Current functioning: general functioning of the
patient in the past 4 weeks (2) System specific involve-
ment, to gain insight in the functioning of individual
organ-systems, (3) Current clinical assessment, a general
and neurological clinical examination, gives insight in
the current clinical functional status of the patient. Sec-
tion 1 to 3 of the NMDAS consists respectively of ten,
nine and ten questions, which can be scored from 0 (no
involvement) to 5 (severe involvement). A NMDAS
score of 0 indicates no clinical manifestation, NMDAS
scores of 1 to 5 were defined as mild clinical manifest-
ation, scores 6 to 20 as moderate and scores above 20 as
severe clinical manifestation [10].
Fear of Progression was assessed with the Dutch trans-
lation of the FoP-Q-SF [12–14]. The FoP-Q-SF consists
of 12 items pertaining to four dimensions (affective reac-
tions, partnership/family issues, occupation and loss of
autonomy) that are scored from 1 (never) to 5 (very
often), where higher scores indicate more FoP. A cut-off
score of ≥34 was used to define high FoP [15, 16].
Quality of life was assessed with the RAND-SF36. The
RAND-SF36 assesses several dimensions of quality of life
(physical functioning, social functioning, emotional func-
tioning, general health status, perceived change in health
status, fatigue and pain). Scores on different scales range
from 0 (maximum limitations) to 100 (optimal function-
ing) [17, 18].
Mental functioning was assessed with the Hospital
Anxiety and Depression Scale (HADS). This question-
naire includes 14 items divided into two subscales (De-
pression and Anxiety), each with seven items. Higher
scores indicate more anxiety, depression, and psycho-
logical distress. The HADS does not contain any somatic
items that could be confounded with symptoms associ-
ated with a physical illness. A total score of 11 or higher
indicates high distress [19, 20].
Data-analyses
Data analysis was performed using SPSS version 22.0.
Descriptive statistics were used to describe the char-
acteristics of the sample as well as patient reported
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outcomes on FoP, quality of life, and mental func-
tioning. Correlational analyses identified the main
correlates of FoP with demographical, disease-related
and psychological variables. To categorize the re-
sults, Cohen’s effect size categories were used: small
(|r| ≤ 0.3), moderate (0.3 < |r| < 0.5), or large (|r| ≥
0.5) [21].
Results
Sample characteristics
Of 125 eligible patients with the m.3243 A > G muta-
tion, 76 patients completed the questionnaires, a re-
sponse rate of 61%. Demographic characteristics are
displayed in Table 1. Differences between response
group and non-responders were assessed on demo-
graphic and clinical characteristics. There were no dif-
ferences between responders and non-responders with
regard to age (t(122) = −.77, p = .45) or gender (Χ2(1)
= 3.17, p = .08). For clinical characteristics, the groups
did not differ on levels of heteroplasmy, NMDAS
subscales or total NMDAS score.
Genotype
Levels of heteroplasmy were assessed in leucocytes
(M = 19,9%; SD = 12.9; range 0–56), urinary epithe-
lial cells (M = 51.0%; SD = 25.1; range 5–96) and
buccal mucosa (M = 34.4%; SD = 14.8; range 2–63).
Disease manifestation
Mean total NMDAS score was 17.7 (SD = 15.5) vary-
ing from 0 to 86. Of the total sample, three patients
were asymptomatic (“dormant carrier” of the muta-
tion), 17% of the patients showed mild symptoms,
45% moderate and 33% had severe symptoms of mito-
chondrial disease.
Relationship genotype and disease manifestation
Significant correlations were found between NMDAS
total scores and levels of heteroplasmy in leucocytes
(r = .275, p = .03), levels of heteroplasmy in urinary epi-
thelial cells (r = .270, p = .03), and levels of heteroplasmy
in buccal mucosa (r = .438, p = .001). Furthermore, a sig-
nificant correlation was found between clinical severity
(as indicated by mild, moderate or severe) and levels of
heteroplasmy in buccal mucosa (r = .475, p < .001). No
significant correlations were found between clinical se-
verity and levels of heteroplasmy in leucocytes or urinary
epithelial cells.
Fear of progression
Cronbach’s alpha for the FoP-Q-SF in this sample
was 0.84. The FoP mean score (FoP-Q-SF) was 26.2
(SD = 7.7; range 12–41). By applying the cutoff
score ≥ 34, 14 patients (18.4%) were classified as hav-
ing high FoP. Means and standard deviations for the
individual items of the FoP-Q-SF are displayed in
Table 2. Highest mean scores were related to the
possibility that children can inherit the disease, pro-
gression of the disease and worrying about family
when something would happen with the patient.
Lowest mean scores were related to medical appoint-
ments or treatments.
Quality of life
Table 3 shows the mean (±SD) scores for the quality of
life domains as assessed by the RAND-36. Scores on the
subscales of the RAND-36 ranged from 44.2 to 73.2, in-
dicating a moderate quality of life. Patients reported gen-
eral health status, perceived change in health status and
fatigue to be significant problems.
Mental functioning
Mean scores for the HADS total score (M = 10.3, SD =
6.8) and subscales anxiety (M = 5.2, SD = 3.5) and de-
pression (M = 5.1, SD = 4.1) were calculated. Results in-
dicated that 25 and 26.3% of the patients indicated
clinical relevant symptoms of respectively anxiety and
depression. By applying the cut-off score of ≥11 on the
total score, 46% of the patients experienced clinical rele-
vant levels of general distress.
Table 1 Sample characteristics (n = 76)
Mean Median Range
Age (years) 47.3 47.6 15–69
Heteroplasmy level
Leucocytes 19.9 17.0 0–56
Urine epithelial cells 51.0 50.0 5–96
Buccal mucosa 34.4 34.5 2–63
NMDAS
1 current functioning 8.1 6.0 0–43
2 system specific involvement 6.5 6.0 0–30
3 current clinical assessment 3.3 1.0 0–33
Total NMDAS 17.7 16.0 0–86
N %
Gender: male 20 26%
Marital status
Married/partnership 62 82%
Children: yes 55 72%
Educational level
Primary 6 8%
Secondary 46 61%
Tertiary 24 31%
Employment status: paid work 36 47%
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Relationship fear of progression and demographical,
medical and psychosocial variables
Fear of progression and demographics
Fear of progression was not related to age (r = −.07,
p = .548; t(74) = .20, p = .84). A marginally significant rela-
tionship (t(74) = − 1.9, p = .06) was found between gender
and FoP indicating that women (M = 27.2, SD = 7.9) tended
to experience more FoP compared to men (M = 23.4, SD =
6.7). No significant relationships were found between FoP
and marital status (p = .20), having children (p = .51), level
of education (p = .53) or employment status (p = .36).
Fear of progression and medical related variables
No significant correlations were found between FoP and
NMDAS scores. To assess the extend to what FoP was
related to the degree of disease manifestation a one-way
ANOVA was performed with three NMDAS categories
(mild, moderate, severe) and FoP as dependent variable.
Results indicated that scores on FoP differed signifi-
cantly between NMDAS severity groups (F(2,71) = 3.59,
p = .03). Patients in the moderate (M = 27.4; SD = 8.4)
and severe (M = 27.6; SD = 6.6) group experienced sig-
nificantly more FoP than patients in the mild group (M
= 21.3; SD = 6.6).
With regard to genotype, a small but significant rela-
tionship was found between FoP and levels of hetero-
plasmy in leucocytes (r = .28, p = .03) and a moderate
but significant relationship between FoP and levels of
heteroplasmy in buccal mucosa (r = .31, p = .02). No sig-
nificant relationship was found between FoP and levels
of heteroplasmy in urine epithelial cells (p = .64).
Fear of progression and psychosocial variables
With regard to quality of life, moderate significant corre-
lations were found between FoP and physical function-
ing (r = −.47, p < .001), social functioning (r = −.39,
p < .001), general health status (r = −.48, p < .001), pain
(r = −.40, p < .001) and fatigue (r = −.44, p < .001). Small
relationships were found between FoP and perceived
change in health status (r = −.27, p = .02) and emotional
functioning (r = −.29, p = .01).
For mental functioning, FoP was moderately correlated
with depression (r = .37, p = .001), anxiety (r = .44,
p < .001), and general distress (r = .45, p < .001).
Discussion
This is the first exploratory study to investigate fear of
progression and one of the few studies reporting on qual-
ity of life in patients with a MELAS spectrum disorder.
About one-fifth (18.4%) of the patients showed elevated
levels of FoP and 46% reported clinical levels of general
distress. Furthermore, patients reported a moderate qual-
ity of life with problems reported on general health status
and fatigue. FoP was moderately related to components of
quality of life, mental health and medical variables. Fur-
thermore, higher levels of heteroplasmy were small but
significantly correlated with more disease manifestation. It
was hypothesized that FoP would be high in patients with
a MELAS spectrum disorder given its uncertain and un-
predictable disease course, premature knowledge about its
Table 2 Mean scores of individual FoP-Q-SF items
Item Meana SD
1. Being afraid of disease progression 2.58 0.93
2. Being nervous prior to doctor’s appointments or periodic examinations 1.87 0.94
3. Being afraid of pain 2.03 0.98
4. Being afraid of becoming less productive at work 2.09 1.10
5. Having physical symptoms (e.g., rapid heartbeat, stomache ache) 2.13 1.04
6. Being afraid of the possibility that the children could contract the disease 2.63 1.51
7. Being afraid of relying on strangers for activities of daily living 2.24 1.04
8. Being afraid of no longer being able to pursue hobbies 2.39 1.03
9. Being afraid of severe medical treatments in course of illness 1.88 0.85
10. Worrying that medications could damage the body 1.84 0.94
11. Worrying what will become of family if something happens to me 2.51 1.13
12. Being afraid of not being able to work anymore 1.99 1.13
aOn a 5-point Likert scale, where 1 = never and 5 = very often
Table 3 Quality of life (RAND-36) scores
Mean SD
Physical functioning 69.1 24.7
Social functioning 69.9 22.7
Emotional functioning 72.9 16.6
General health status 44.2 23.8
Perceived change in health status 44.7 22.5
Pain 73.2 26.0
Fatigue 56.6 21.3
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character and absence of treatment possibilities. Com-
pared to other studies using the FoP-Q-SF the percentage
of high FoP found in this study was lower (e.g.
hematological cancer 23–26%) [15, 16]. Furthermore the
mean FoP score of patients with a MELAS spectrum dis-
order was significant lower than patients with systemic
sclerosis [14] and patients with breast cancer [22]. Inspec-
tion of the single items of the FoP-Q-SF revealed that car-
riers were most afraid of the possibility that their children
could inherit the disease, progression of the disease and
worrying about their family if something happens to them.
These results confirm that dealing with this mitochondrial
disease is characterized by dealing with uncertainty about
future, disease course and hereditary concerns. This is
different for other groups whereas cancer patients pre-
dominantly fear dying and the unpredictability of pro-
gression. Patients with chronic arthritis fear being
physically dependent on others and the most common
anxiety of patients with diabetes are long-term compli-
cations [1]. Insight in why patients react differently to
the news that they have a mitochondrial disease and
why some are more fearful than others for disease pro-
gression could be provided by Leventhal’s Self Regula-
tion Model of Illness [23]. External and internal stimuli
generate a subjective perception of a health threat and
concomitant emotions (e.g. fear/distress), leading to
coping strategies and appraisal of health outcomes. In-
ternal stimuli might be interpreted as reminders of
threat that the disease progresses. This study demon-
strates that patients with moderate and severe clinical
symptoms as assessed by the NMDAS reported higher
FoP indicating that the presence of symptoms is associ-
ated with higher fear. External triggers such as medical
appointments could also increase worry about disease
status and disease course. However, in this study pa-
tients reported low fear scores on the item of the
FoP-Q-SF whether they are nervous prior to doctor’s ap-
pointments or periodic examinations. Given the fact that
the Radboud Center for Mitochondrial Medicine is the
expert center for mitochondrial disorders in the
Netherlands, patients might feel reassured by the expert-
ise and well arranged care in this center, and therewith
this could be a buffer for excessive fear of progression.
Although the percentage of FoP was not as high as hy-
pothesized, a considerable percentage of patients (46%)
experienced clinical levels of general distress defined as
a complex, unpleasant emotional experience character-
ized by comprised psychological, social and/or spiritual
wellbeing [24]. Given that both general distress and FoP
are associated with a lower quality of life and restrictions
or problems in daily life, it is important in this patient
group to assess mental functioning in clinical consulta-
tions and assist patients in accessing appropriate and
available support.
A limitation of this study is its cross-sectional design.
Longitudinal research could elaborate the role of FoP as
mediator between medical history and personal character-
istics as antecedents and functioning and quality of life as
consequences. Furthermore, given the uncertain and un-
predictable character of the disease a valid and reliable
measurement for uncertainty could have shed light on this
issue in this research. For further research it would be in-
teresting to measure uncertainty and its correlates. With
regard to measurement issues another limitation is the
use of the cut-off score of the FoP-Q-SF, validated in a
sample of hematological cancers. Future research should
replicate the validation of this cut-off score in a sample of
patients with a mitochondrial disorder. Therewith both re-
search and clinical practice could contribute to support
these patients in dealing with their disease.
Conclusions
In conclusion, a substantial percentage of patients with a
MELAS spectrum disorder reported considerable levels of
FoP and distress coinciding with impairments in their qual-
ity of life. Therefore, it is important to integrate assessments
of mental functioning in clinical consultations in order to as-
sist patients in accessing appropriate and available support.
Based on the findings of this study, further research
should elaborate on the concept of uncertainty about the fu-
ture and should replicate and validate the cut-off score for
FoP in a more heterogeneous sample of patients with di-
verse mitochondrial disorders. Furthermore, with regard to
hereditary concerns, it might be interesting to investigate
clusters of families affected by a mitochondrial disease and
the influence of having family with the same progressive dis-
ease on fear of progression and uncertainty for the future.
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